The Joint Corp. (JYNT)
USD 10.08
(0.6%)
USD 10.08
(0.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.14 Million USD | -13.28% |
| 2022 | 7.88 Million USD | -13.32% |
| 2021 | 12.16 Million USD | 49.69% |
| 2020 | 8.17 Million USD | 47.09% |
| 2019 | 5.42 Million USD | 91.03% |
| 2018 | 2.29 Million USD | 998.93% |
| 2017 | -896.78 Thousand USD | 94.06% |
| 2016 | -8.84 Million USD | 34.82% |
| 2015 | -7.76 Million USD | -486.53% |
| 2014 | -1.41 Million USD | -377.48% |
| 2013 | 510.51 Thousand USD | 139.35% |
| 2012 | -1.29 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -60.15 Thousand USD | -118.87% |
| 2024 Q1 | 2.85 Million USD | -6.63% |
| 2023 FY | - USD | -13.28% |
| 2023 Q3 | 3.26 Million USD | 45.36% |
| 2023 Q4 | 3.05 Million USD | -6.19% |
| 2023 Q1 | 1.79 Million USD | -51.25% |
| 2023 Q2 | 2.24 Million USD | 24.96% |
| 2022 Q4 | 3.68 Million USD | 21.09% |
| 2022 Q1 | 1.46 Million USD | -41.5% |
| 2022 Q2 | 2.35 Million USD | 60.33% |
| 2022 Q3 | 3.04 Million USD | 29.33% |
| 2022 FY | - USD | -13.32% |
| 2021 Q1 | 3.27 Million USD | -5.23% |
| 2021 FY | - USD | 49.69% |
| 2021 Q2 | 3.38 Million USD | 3.6% |
| 2021 Q3 | 2.99 Million USD | -11.65% |
| 2021 Q4 | 2.5 Million USD | -16.28% |
| 2020 Q1 | 1.4 Million USD | -26.9% |
| 2020 Q2 | 842.77 Thousand USD | -40.23% |
| 2020 Q3 | 2.41 Million USD | 187.11% |
| 2020 FY | - USD | 47.09% |
| 2020 Q4 | 3.45 Million USD | 42.65% |
| 2019 Q4 | 1.92 Million USD | 55.75% |
| 2019 Q2 | 855.53 Thousand USD | -38.68% |
| 2019 Q1 | 1.39 Million USD | 5.09% |
| 2019 FY | - USD | 91.03% |
| 2019 Q3 | 1.23 Million USD | 44.76% |
| 2018 Q3 | 884.47 Thousand USD | 21.04% |
| 2018 FY | - USD | 998.93% |
| 2018 Q4 | 1.32 Million USD | 50.11% |
| 2018 Q2 | 730.71 Thousand USD | 1514.8% |
| 2018 Q1 | -51.64 Thousand USD | -121.38% |
| 2017 Q1 | -173.06 Thousand USD | -108.8% |
| 2017 FY | - USD | 94.06% |
| 2017 Q4 | 241.58 Thousand USD | 164.98% |
| 2017 Q3 | 91.17 Thousand USD | 118.94% |
| 2017 Q2 | -481.32 Thousand USD | -178.12% |
| 2016 Q1 | -2.91 Million USD | 0.84% |
| 2016 FY | - USD | 34.82% |
| 2016 Q4 | 1.96 Million USD | 202.51% |
| 2016 Q3 | -1.91 Million USD | 24.86% |
| 2016 Q2 | -2.55 Million USD | 12.24% |
| 2015 Q1 | -1.8 Million USD | -107.83% |
| 2015 Q3 | -2.01 Million USD | -28.46% |
| 2015 Q2 | -1.56 Million USD | 13.11% |
| 2015 Q4 | -2.93 Million USD | -45.74% |
| 2015 FY | - USD | -486.53% |
| 2014 FY | - USD | -377.48% |
| 2014 Q1 | -117.32 Thousand USD | -172.67% |
| 2014 Q4 | -868.09 Thousand USD | -236.47% |
| 2014 Q2 | -160.33 Thousand USD | -36.66% |
| 2014 Q3 | -258 Thousand USD | -60.91% |
| 2013 Q3 | 212.88 Thousand USD | 0.0% |
| 2013 Q4 | 161.43 Thousand USD | -24.16% |
| 2013 FY | - USD | 139.35% |
| 2012 FY | - USD | 0.0% |
| 2001 Q3 | 2.98 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acadia Healthcare Company, Inc. | 189.11 Million USD | 95.166% |
| Addus HomeCare Corporation | 106.55 Million USD | 91.421% |
| AirSculpt Technologies, Inc. | 28.31 Million USD | 67.711% |
| Amedisys, Inc. | 216.91 Million USD | 95.786% |
| American Oncology Network, Inc. | -39.35 Million USD | 123.231% |
| Astrana Health, Inc. | 123.68 Million USD | 92.609% |
| Aveanna Healthcare Holdings Inc. | 44.34 Million USD | 79.386% |
| IMAC Holdings, Inc. | -5.94 Million USD | 253.725% |
| biote Corp. | 9.23 Million USD | 0.999% |
| Cryo-Cell International, Inc. | -10.41 Million USD | 187.755% |
| Cross Country Healthcare, Inc. | 129.33 Million USD | 92.932% |
| COMPASS Pathways plc | -123.8 Million USD | 107.384% |
| DocGo Inc. | 32.72 Million USD | 72.065% |
| The Ensign Group, Inc. | 353.23 Million USD | 97.412% |
| Healthcare Services Group, Inc. | 75.21 Million USD | 87.845% |
| InnovAge Holding Corp. | 1.15 Million USD | -692.177% |
| Assure Holdings Corp. | -19.82 Million USD | 146.114% |
| LifeStance Health Group, Inc. | -104.92 Million USD | 108.713% |
| Mobile-health Network Solutions Class A Ordinary Shares | -15.55 Million USD | 158.772% |
| ModivCare Inc. | -26.75 Million USD | 134.175% |
| NewGenIvf Group Limited | 384.3 Thousand USD | -2278.767% |
| Novo Integrated Sciences, Inc. | -5.84 Million USD | 256.295% |
| Option Care Health, Inc. | 376.79 Million USD | 97.574% |
| P3 Health Partners Inc. | -81.07 Million USD | 111.276% |
| P3 Health Partners Inc. | -81.07 Million USD | 111.276% |
| The Pennant Group, Inc. | 30.36 Million USD | 69.898% |
| Surgery Partners, Inc. | 446.1 Million USD | 97.951% |
| Syra Health Corp. Class A Common Stock | -2.83 Million USD | 422.359% |
| Talkspace, Inc. | -22.01 Million USD | 141.529% |
| Talkspace, Inc. | -22.01 Million USD | 141.529% |
| The Oncology Institute, Inc. | -70.45 Million USD | 112.975% |
| The Oncology Institute, Inc. | -70.45 Million USD | 112.975% |